ClinicalTrials.gg
Not yet recruitingNCT07460284Updated Mar 10, 2026

A Mass Balance Study Of 14C-RAY1225 Injection In Healthy Chinese Participants

A Phase 1 interventional study of 14C-RAY1225 in Basic Science, sponsored by Guangdong Raynovent Biotech Co., Ltd. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-10.

Sponsored by Guangdong Raynovent Biotech Co., Ltd (part of Guangdong Zhongsheng Pharmaceutical Co., Ltd.) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is an open-label, single-center, single-dose study.

02

Conditions studied

  • Basic Science
03

In context

Lead sponsor

Guangdong Raynovent Biotech Co., Ltd is the lead sponsor of 36 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants who sign the form, fully understand the content, process, and possible adverse reactions of the study, and are able to complete the study as required by the study protocol;
  2. Healthy adult males aged 18-55 years (inclusive, based on the time of signing the ICF);
  3. Weight ≥ 50 kg, and (BMI) = weight (kg)/height2 (m 2) between 20.0-35.0 kg/m2 (inclusive);
  4. Participants (including partners) who agree to voluntarily use effective from screening until 6 months after the drug administration and have no sperm donation plan. For specific contraceptive measures

Exclusion criteria

Exclusion Criteria:

  1. Subjects with trauma, surgical scar, or skin lesions at the proposed administration site (abdomen) who are not suitable for subcutaneous injection as assessed by the investigator;
  2. History of hypoglycemic episodes within 12 months prior to screening;
  3. Major surgery or serious infection within 12 weeks prior to screening;
  4. Acute disease from the signing of the ICF to the administration of the drug;
  5. Smoking more than 5 cigarettes per day within 12 weeks prior to screening, or unable to abstain from smoking within 7 days prior to admission and during the study;
  6. Participants who are not otherwise eligible to participate in this study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (estimated)

Study arms

  • Experimental
    RAY1225

    Drug: 14C-RAY1225

Interventions

  • Drug14C-RAY1225

    subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Total radioactivity recovery and cumulative recovery in urine and feces in each time period;

    To quantitatively analyze the total radioactivity in the excretions of healthy participants after subcutaneous injection of 14C-RAY1225, and to obtain the primary radioactivity recovery data and primary excretion pathways in humans;

    Time frame: DAY1~DAY60

  2. Radioactivity of each metabolite in urine and feces as a percentage of the total administered dose and the circulating metabolites in plasma as a percentage of the total exposure AUC (%AUC);

    Time frame: DAY1~DAY60

Secondary outcomes

  1. Occurrence of adverse events/significant adverse events/serious adverse events

    Time frame: DAY1~DAY60

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2026; primary completion for Oct 2026, 6 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2026
First posted
Mar 10, 2026
StartEst.
Mar 15, 2026
Primary completionEst.
Oct 14, 2026
CompletionEst.
Oct 28, 2026
Last update
Mar 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07460284
Responsible party
Sponsor
First posted
Mar 10, 2026
Start date
Mar 15, 2026 (estimated)
Primary completion
Oct 14, 2026 (estimated)
Completion
Oct 28, 2026 (estimated)
Last update
Mar 10, 2026

Study contacts

Zhao, Professor
Contact
qylcsyllwyh@163.com
053189268311

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion